XML 10 R4.htm IDEA: XBRL DOCUMENT v3.25.3
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Net revenues $ 4,480 $ 4,332 $ 12,547 $ 12,315
Cost of sales 2,176 2,183 6,264 6,372
Gross profit 2,304 2,148 6,282 5,943
Research and development expenses 256 240 746 751
Selling and marketing expenses 656 626 1,933 1,891
General and administrative expenses 317 298 920 859
Intangible assets impairments 64 28 227 169
Goodwill impairment 0 600 0 1,000
Other assets impairments, restructuring and other items 62 (23) 272 931
Legal settlements and loss contingencies 60 450 312 638
Other loss (income) 7 (21) 15 (22)
Operating income (loss) 882 (51) 1,857 (274)
Financial expenses, net 237 272 714 763
Income (loss) before income taxes 646 (324) 1,143 (1,037)
Income taxes (benefit) 214 69 210 648
Share in (profits) losses of associated companies, net (2) (3) (4) (1)
Net income (loss) 434 (390) 937 (1,684)
Net income (loss) attributable to redeemable and non-redeemable non-controlling interests 1 47 7 (262)
Net income (loss) attributable to Teva $ 433 $ (437) $ 930 $ (1,422)
Earnings (loss) per share attributable to ordinary shareholders:        
Basic $ 0.38 $ (0.39) $ 0.81 $ (1.26)
Diluted $ 0.37 $ (0.39) $ 0.8 $ (1.26)
Weighted average number of shares (in millions):        
Basic 1,147 1,133 1,144 1,130
Diluted 1,164 1,133 1,160 1,130